“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...
Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
Cell-line development enhances biopharmaceutical production capacity and quality, but complex biologics like bsAbs and ADCs present new challenges.
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
A Stanford-led study probes why a very small number of people develop heart inflammation shortly after mRNA COVID-19 ...
The BioMarin Pharmaceutical Inc. acquisition of Amicus Therapeutics, Inc. will likely be beneficial and accretive for both ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
Plymouth Meeting, Pennsylvania Tuesday, December 30, 2025, 15:00 Hrs [IST] ...
Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies([1]) , with the FDA fast-tracking multiple targeted therapies designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback